Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer

Cancer Research

Volumn 60, Issue 23, 2000, Pages 6630-6640

  Long, B J ^a   Grigoryev, D N ^a   Nnane, I P ^a   Liu, Y ^a   Ling, Y Z ^a   Brodie, A M ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 (2' IMIDAZOLYL)ANDROSTA 5,16 DIEN 3BETA OL; 17 (3' PYRAZOLYL)ANDROSTA 4,16 DIEN 3 ONE; 17 (3' PYRAZOLYL)ANDROSTA 5,16 DIEN 3BETA OL; 17 (5' ISOXAZOLYL)ANDROSTA 4,16 DIEN 3 ONE; 20 HYDROXIMINO 4,16 PREGNADIEN 3 ONE; 20BETA HYDROXY 4,16 PREGNADIEN 3 ONE; ANDROSTANE DERIVATIVE; ANDROSTANOLONE; ANTIANDROGEN; FINASTERIDE; FLUTAMIDE; KETOCONAZOLE; LUCIFERASE; METRIBOLONE; PREGNANE DERIVATIVE; TESTOSTERONE; TRIAMCINOLONE ACETONIDE; TRITIUM; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; CANCER GROWTH; CONTROLLED STUDY; DRUG STRUCTURE; GENETIC TRANSFECTION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; REPORTER GENE; SCID MOUSE; TESTOSTERONE BLOOD LEVEL; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; CERCOPITHECUS AETHIOPS; FINASTERIDE; GROWTH INHIBITORS; HUMANS; KETOCONAZOLE; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; OLEANOLIC ACID; PREGNADIENES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SAPONINS; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034541199     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Cancer statistics
2. Prostate cancer incidence and mortality in the United States and the United Kingdom
3. Endocrinology of the prostate
4. The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro
5. The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
6. Role of dihydrotestosterone action in androgen action
7. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
8. Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, Phase III: Intergroup study 0036
9. Role of maximal androgen blockade in advanced prostate cancer
10. 21 steroid side chain cleavage: Spectral and binding studies
11. Cytochrome P450c17 (steroid 17 α-hydroxylase/17,20 lyase): Cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues
12. Ketoconazole therapy for advanced prostatic cancer
13. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer
14. High dose ketoconazole for the treatment of hormone-refractory metastatic prostate cancer: 16 cases and review of the literature
15. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma
16. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
17. Inhibition of steroid 5 α-reductase with finasteride: Sleep-related erections, potency, and libido in healthy men
18. Finasteride: A review of its potential in the treatment of benign prostatic hyperplasia
19. Effects of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate specific antigen
20. Role of 5α-reductase inhibitors in the treatment of advanced prostatic carcinoma
21. Role of androgens in prostatic cancer
22. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatment of 'hormone-refractory' prostate cancer
23. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
24. Inhibition of androgen synthesis by 22-hydroxyamino-23,24-bisnor-4-cholen-3-one
25. 17.20lyase and of 5α-reductase
26. 17.20lyase
27. 17.20lyase (P-450(17αa))
28. 17.20-lyase (P-450(17αa)): Potent inhibitors for the treatment of prostate cancer
29. LNCaP model of human prostatic carcinoma
30. Preclinical models of prostate cancer
31. Characterization of a novel androgen-sensitive, prostate specific antigen-producing prostatic carcinoma xenograft
32. Androgen-dependent growth regulation and release of specific proteins by the androgen receptor containing human prostate tumor cell line LNCaP
33. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens
34. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth. EGF-receptor level and acid phosphatase secretion
35. Immortalization and tumorigenic adult human prostatic epithelial cell lines; characteristics and applications. Part 2. Tumorigenic cell lines
36. Altered growth and insulin-like growth factor-binding protein-3 production in PC-3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid
37. Transcriptional activation and transient expression of the human androgen receptor
38. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line
39. 17.20-lyase inhlbitors
40. Androgen receptor antagonist versus agonist activities of the fungicide vinclozin relative to hydroxyflutamide
41. A single base mutation in the androgen receptor gene causes androgen insensitivity in the testicular feminized rat
42. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice
43. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatize gene
44. Effects of aromatize inhibitors on growth of mammary tumors in a nude mouse model
45. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis
46. 17.20-lyase inhibitors on the growth of LNCaP prostate cancer cells in vitro and in vivo
47. 17.20-lyase and 5α-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer
48. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds
49. Ligand responsiveness in human prostate cancer: Structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors
50. Aberrant responses in vitro of hormone responsive prostate cancer cells to antiandrogens
51. Anti-androgens and mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation
52. Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cells
53. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
54. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
55. The development of Casodex (bicalutamide): Preclinical studies
56. Bicalutamide (Casodex) in the treatment of prostate cancer: History of clinical development
57. Which is the optimal antiandrogen to use in combined androgen blockade of advanced prostate cancer? The transition from a first- to a second-generation antiandrogen
58. Characteristics of the biphasic action of androgens and the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells
59. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: An inhibitor of androgen synthesis